Clinical Aspects of Multi-Drug Resistant Enterococci



During the last few years, the prevalence of multidrug drug resistant enterococci has been steadily increasing around the world, and remarkable changes in the epidemiology of enterococcal infections have been documented. Enterococci have the most striking ability to carry and transfer multiple determinants of antimicrobial resistance along with factors that enable them to colonize the gastrointestinal tract of hospitalized individuals (which acts as a reservoir for transmission), and subsequently, cause disease. Multidrug drug-resistant enterococci transmission resembles a vector borne disease with the health care workers playing the role of the mosquito in the infection cascade. Thus, the implementation of infection control measures is one of the most important strategies to curtail dissemination of this important pathogen. Multiple antibiotics with anti-enterococcal activity have recently reached clinical practice (i.e., daptomycin, linezolid, tigecycline) whereas others are under development; however, the rapid development of resistance to these new compounds, in this versatile pathogen, compromises most of the current and future therapeutic choices available for the treatment of enterococcal infections. The clinical challenge posed by enterococci is enormous, and a response of the same magnitude requires a concerted effort between scientists and clinicians.


Health Care Worker Soft Tissue Infection Enterococcal Infection Enterococcal Isolate Linezolid Therapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



Aminoglycoside Phosphotransferase.


Aminoglycoside Nucleotidyltransferases.


Aminoglycoside Phosphotransferase.


Health Care Worker.


High Level of Aminoglycoside Resistance.


Minimal Inhibitory Concentration.


Macrolides Lincosamides Streptogramine B.


Multi Locus Sequence Typing.


Methicillin Resistant Staphylococcus aureus.


Penicillin Binding Protein.


Vancomycin Resistant Enterococci.


Vancomycin Resistant Enterococcus faecium.


Vancomycin Resistant Enterococcus faecalis.


  1. 1.
    Akins RL, Rybak MJ (2001) Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother 45(2):454–459PubMedGoogle Scholar
  2. 2.
    Aksoy DY, Unal S (2008) New antimicrobial agents for the treatment of Gram-positive bacterial infections. Clin Microbiol Infect 14(5):411–420PubMedGoogle Scholar
  3. 3.
    Allen NE, Nicas TI (2003) Mechanism of action of oritavancin and related glycopeptides antibiotics. FEMS Microbiol Rev 26(5):511–532PubMedGoogle Scholar
  4. 4.
    Antony SJ, Ladner J, Stratton CW et al (1997). High-level aminoglycoside-resistant enterococcus causing endocarditis successfully treated with a combination of ampicillin, imipenem and vancomycin. Scand J Infect Dis 29(6):628–630PubMedGoogle Scholar
  5. 5.
    Arhin FF, Sarmiento I, Belley A et al (2008) Effect of polysorbate 80 on oritavancin binding to plastic surfaces: implications for susceptibility testing. Antimicrob Agents Chemother 52(5):1597–1603PubMedGoogle Scholar
  6. 6.
    Arias CA, Murray BE (2008) Emergence and management of drug-resistant enterococcal infections. Expert Rev Anti Infect Ther 6(5):637–655PubMedGoogle Scholar
  7. 7.
    Arias CA, Singh KV, Panesso D et al (2007) Evaluation of ceftobiprole medocaril against Enterococcus faecalis in a mouse peritonitis model. J Antimicrob Chemother 60(3):594–598PubMedGoogle Scholar
  8. 8.
    Arias CA, Singh KV, Panesso D et al (2007) Time-kill and synergism studies of ceftobiprole against Enterococcus faecalis, including beta-lactamase-producing and vancomycin-resistant isolates. Antimicrob Agents Chemother 51(6):2043–2047PubMedGoogle Scholar
  9. 9.
    Arias CA, Torres HA, Singh KV et al (2007) Failure of daptomycin monotherapy for endocarditis caused by an Enterococcus faecium strain with vancomycin-resistant and vancomycin-susceptible subpopulations and evidence of in vivo loss of the vanA gene cluster. Clin Infect Dis 45(10):1343–1346PubMedGoogle Scholar
  10. 10.
    Arias CA, Vallejo M, Reyes J et al (2008) Clinical and microbiological aspects of linezolid resistance mediated by the cfr gene encoding a 23 S rRNA methyltransferase. J Clin Microbiol 46(3):892–896PubMedGoogle Scholar
  11. 11.
    Arias CA, Reyes J, Zúñiga M et al (2003). Multicentre surveillance of antimicrobial resistance in enterococci and staphylococci from Colombian hospitals, 2001–2002. J Antimicrob Chemother 51(1):59–68PubMedGoogle Scholar
  12. 12.
    Atta MG, Eustace JA, Song X et al (2001) Outpatient vancomycin use and vancomycin-resistant enterococcal colonization in maintenance dialysis patients. Kidney Int 59(2):718–724PubMedGoogle Scholar
  13. 13.
    Austin DJ, Bonten MJ, Weinstein RA et al (1999) Vancomycin-resistant enterococci in intensive-care hospital settings: transmission dynamics, persistence, and the impact of infection control programs. Proc Natl Acad Sci USA 96(12):6908–6913PubMedGoogle Scholar
  14. 14.
    Babinchak T, Ellis-Grosse E, Dartois N et al (2005) The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Clin Infect Dis 41(Suppl 5):S354–S367PubMedGoogle Scholar
  15. 15.
    Baden LR, Thiemke W, Skolnik A et al (2001) Prolonged colonization with vancomycin-resistant Enterococcus faecium in long-term care patients and the significance of “clearance”. Clin Infect Dis 33(10):1654–1660PubMedGoogle Scholar
  16. 16.
    Bagshaw SM, Laupland KB (2006) Epidemiology of intensive care unit-acquired urinary tract infections. Curr Opin Infect Dis 19(1):67–71PubMedGoogle Scholar
  17. 17.
    Baltch AL, Smith RP, Ritz WJ et al (1998) Comparison of inhibitory and bactericidal activities and postantibiotic effects of LY333328 and ampicillin used singly and in combination against vancomycin-resistant Enterococcus faecium. Antimicrob Agents Chemother 42(10):2564–2568PubMedGoogle Scholar
  18. 18.
    Barriere JC, Berthaud N, Beyer D et al (1998) Recent developments in streptogramin research. Curr Pharm Des 4(2):155–180PubMedGoogle Scholar
  19. 19.
    Berdal JE, Eskesen A (2008) Short-term success, but long-term treatment failure with linezolid for enterococcal endocarditis. Scand J Infect Dis 40(9):765–766PubMedGoogle Scholar
  20. 20.
    Bergeron J, Ammirati M, Danley D et al (1996) Glycylcyclines bind to the high-affinity tetracycline ribosomal binding site and evade Tet(M)- and Tet(O)-mediated ribosomal protection. Antimicrob Agents Chemother 40(9):2226–2228PubMedGoogle Scholar
  21. 21.
    Bethea JA, Walko CM, Targos PA (2004) Treatment of vancomycin-resistant enterococcus with quinupristin/dalfopristin and high-dose ampicillin. Ann Pharmacother 38(6):989–991PubMedGoogle Scholar
  22. 22.
    Bhavnani SM, Owen JS, Loutit JS et al (2004) Pharmacokinetics, safety, and tolerability of ascending single intravenous doses of oritavancin administered to healthy human subjects. Diagn Microbiol Infect Dis 50(2):95–102PubMedGoogle Scholar
  23. 23.
    Billeter M, Zervos MJ, Chen AY et al (2008) Dalbavancin: a novel once-weekly lipoglycopeptide antibiotic. Clin Infect Dis 46(4):577–583PubMedGoogle Scholar
  24. 24.
    Birmingham MC, Rayner CR, Meagher AK et al (2003) Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program. Clin Infect Dis 36(2):159–168PubMedGoogle Scholar
  25. 25.
    Borgmann S, Schulte B, Wolz C et al (2007) Discrimination between epidemic and non-epidemic glycopeptide-resistant E. faecium in a post-outbreak situation. J Hosp Infect 67(1):49–55Google Scholar
  26. 26.
    Bouza E, Menasalvas A, Munoz P et al (2001) Infective endocarditis–a prospective study at the end of the twentieth century: new predisposing conditions, new etiologic agents, and still a high mortality. Medicine (Baltimore) 80(5):298–307Google Scholar
  27. 27.
    Brandt CM, Rouse MS, Laue NW et al (1996). Effective treatment of multidrug-resistant enterococcal experimental endocarditis with combinations of cell wall-active agents. J Infect Dis 173(4):909–913PubMedGoogle Scholar
  28. 28.
    Brown SD, Traczewski MM (2008) Comparative in vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing. Antimicrob Agents Chemother 66(3):69–80Google Scholar
  29. 29.
    Bryson HM, Spencer CM (1996) Quinupristin-dalfopristin. Drugs 52(3):406–415PubMedGoogle Scholar
  30. 30.
    Candiani G, Abbondi M, Borgonovi M, Romano G, Parenti F (1999) In-vitro and in-vivo antibacterial activity of BI 397, a new semi-synthetic glycopeptide antibiotic. J Antimicrob Chemother 44(2):179–192PubMedGoogle Scholar
  31. 31.
    Caplin JL, Hanlon GW, Taylor HD (2008) Presence of vancomycin and ampicillin-resistant Enterococcus faecium of epidemic clonal complex-17 in wastewaters from the south coast of England. Environ Microbiol 10(4):885–892PubMedGoogle Scholar
  32. 32.
    Casewell M, Friis C, Marco E, McMullin P et al (2003) The European ban on growth-promoting antibiotics and emerging consequences for human and animal health. J Antimicrob Chemother 52(2):159–161PubMedGoogle Scholar
  33. 33.
    Cates JE, Christie RV, Garrod LP (1951) Penicillin resistant sub-acute bacterial endocarditis treated by a combination of penicillin and streptomycin. Brit Med J 1:653–656PubMedGoogle Scholar
  34. 34.
    Celebi S, Hacimustafaoglu M, Ozdemir O et al (2007) Nosocomial Gram-positive bacterial infections in children: results of a 7 year study. Pediatr Int 49(6):875–882PubMedGoogle Scholar
  35. 35.
    Chant C, Rybak MJ (1995) Quinupristin/dalfopristin (RP 59500): a new streptogramin antibiotic. Ann Pharmacother 29(10):1022–1027PubMedGoogle Scholar
  36. 36.
    Chatterjee I, Iredell JR, Woods M et al (2007) The implications of enterococci for the intensive care unit. Crit Care Resusc 9(1):69–75PubMedGoogle Scholar
  37. 37.
    Choi SH, Lee SO, Kim TH et al (2004) Clinical features and outcomes of bacteremia caused by Enterococcus casseliflavus and Enterococcus gallinarum: analysis of 56 cases. Clin Infect Dis 38(1):53–61PubMedGoogle Scholar
  38. 38.
    Chopra I, Roberts M (2001) Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol Mol Biol Rev 65(2):232–260PubMedGoogle Scholar
  39. 39.
    Chow JW (2000) Aminoglycoside resistance in enterococci. Clin Infect Dis 31(2):586–589PubMedGoogle Scholar
  40. 40.
    Chow JW, Kak V, You I et al (2001) Aminoglycoside resistance genes aph(2¬¬)-Ib and aac(6¬)-Im detected together in strains of both Escherichia coli and Enterococcus faecium. Antimicrob Agents Chemother 45(10):2691–2694PubMedGoogle Scholar
  41. 41.
    Christiansen KJ, Turnidge JD, Bell JM et al (2007) Prevalence of antimicrobial resistance in Enterococcus isolates in Australia, 2005: report from the Australian group on antimicrobial resistance. Commun Dis Intell 31(4):392–397PubMedGoogle Scholar
  42. 42.
    Clewell DB (1990) Movable genetic elements and antibiotic resistance in enterococci. Eur J Clin Microbiol Infect Dis 9(2):90–102PubMedGoogle Scholar
  43. 43.
    Cocito C, Di Giambattista M, Nyssen E et al (1997) Inhibition of protein synthesis by streptogramins and related antibiotics. J Antimicrob Chemother 39(Suppl A):7–13Google Scholar
  44. 44.
    Connell SR, Tracz DM, Nierhaus KH et al (2003) Ribosomal protection proteins and their mechanism of tetracycline resistance. Antimicrob Agents Chemother 47(12):3675–3681PubMedGoogle Scholar
  45. 45.
    Contreras GA, Diazgranados CA, Cortes L et al (2008) Nosocomial outbreak of Enteroccocus gallinarum: untaming of rare species of enterococci. J Hosp Infect 70(4):346–352PubMedGoogle Scholar
  46. 46.
    Cooper RD, Snyder NJ, Zweifel MJ et al (1996) Reductive alkylation of glycopeptide antibiotics: synthesis and antibacterial activity. J Antibiot 49(6):575–581 (Tokyo)Google Scholar
  47. 47.
    Cooper MP, Lessa F, Brems B et al (2008) Outbreak of Enterococcus gallinarum infections after total knee arthroplasty. Infect Control Hosp Epidemiol 29(4):361–363PubMedGoogle Scholar
  48. 48.
    Critchley IA, Blosser-Middleton RS, Jones ME et al (2003) Baseline study to determinein vitro activities of daptomycin against gram-positive pathogens isolated in the United States in 2000–2001. Antimicrob Agents Chemother 47(5):1689–1693PubMedGoogle Scholar
  49. 49.
    D’Agata EM, Green WK, Schulman G et al (2001) Vancomycin-resistant enterococci among chronic hemodialysis patients: a prospective study of acquisition. Clin Infect Dis 32(1):23–29PubMedGoogle Scholar
  50. 50.
    Dandekar PK, Tessier PR, Williams P et al (2003) Pharmacodynamic profile of daptomycin against Enterococcus species and methicillin-resistant Staphylococcus aureus in a murine thigh infection model. J Antimicrob Chemother 52(3):405–411PubMedGoogle Scholar
  51. 51.
    de Perio MA, Yarnold PR, Warren J et al (2006) Risk factors and outcomes associated with non-Enterococcus faecalis, non-Enterococcus faecium enterococcal bacteremia. Infect Control Hosp Epidemiol 27(1):28–33PubMedGoogle Scholar
  52. 52.
    de Regt MJ, van der Wagen LE, Top J et al (2008) High acquisition and environmental contamination rates of CC17 ampicillin-resistant Enterococcus faecium in a Dutch hospital. J Antimicrob Chemother 62(6):1401–1406PubMedGoogle Scholar
  53. 53.
    DeLisle S, Perl TM (2003) Vancomycin-resistant enterococci: a road map on how to prevent the emergence and transmission of antimicrobial resistance. Chest 123(5 Suppl):504S–518SPubMedGoogle Scholar
  54. 54.
    Dettenkofer M, Wenzler S, Amthor S et al (2004) Does disinfection of environmental surfaces influence nosocomial infection rates? A systematic review. Am J Infect Control 32(2):84–89PubMedGoogle Scholar
  55. 55.
    DiazGranados CA, Zimmer SM, Klein M et al (2005) Comparison of mortality associated with vancomycin-resistant and vancomycin-susceptible enterococcal bloodstream infections: a meta-analysis. Clin Infect Dis 41(3):327–333PubMedGoogle Scholar
  56. 56.
    Dobbs TE, Patel M, Waites KB et al (2006) Nosocomial spread of Enterococcus faecium resistant to vancomycin and linezolid in a tertiary care medical center. J Clin Microbiol 44(9): 3368–3370PubMedGoogle Scholar
  57. 57.
    Donskey CJ, Chowdhry TK, Hecker MT et al (2000). Effect of antibiotic therapy on the density of vancomycin-resistant enterococci in the stool of colonized patients. N Engl J Med 343(26):1925–1932PubMedGoogle Scholar
  58. 58.
    Dowzicky MJ, Park CH (2008) Update on antimicrobial susceptibility rates among gram-negative and gram-positive organisms in the United States: results from the Tigecycline Evaluation and Surveillance Trial (TEST) 2005 to 2007. Clin Ther 30(11):2040–2050PubMedGoogle Scholar
  59. 59.
    Durand ML, Calderwood SB, Weber DJ et al (1993) Acute bacterial meningitis in adults. A review of 493 episodes. N Engl J Med 328(1):21–28Google Scholar
  60. 60.
    Edmond MB, Ober JF, Weinbaum DL et al (1995) Vancomycin-resistant Enterococcus faecium bacteremia: risk factors for infection. Clin Infect Dis 20(5):1126–1133PubMedGoogle Scholar
  61. 61.
    Eliopoulos GM, Farber BF, Murray BE et al (1984) Ribosomal resistance of clinical enterococcal to streptomycin isolates. Antimicrob Agents Chemother 25(3):398–399PubMedGoogle Scholar
  62. 62.
    Eliopoulos GM, Wennersten C, Zighelboim-Daum S et al (1988) High-level resistance to gentamicin in clinical isolates of Streptococcus (Enterococcus) faecium. Antimicrob Agents Chemother 32(10):1528–1532PubMedGoogle Scholar
  63. 63.
    Ellis-Grosse EJ, Babinchak T, Dartois N et al (2005) The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis 41(Suppl 5):S341–S353PubMedGoogle Scholar
  64. 64.
    Enoch DA, Bygott JM, Daly ML et al (2007) Daptomycin. J Infect 55(3):205–213PubMedGoogle Scholar
  65. 65.
    Falagas ME, Manta KG, Ntziora F et al (2006) Linezolid for the treatment of patients with endocarditis: a systematic review of the published evidence. J Antimicrob Chemother 58(2):273–280PubMedGoogle Scholar
  66. 66.
    Fernandez Guerrero ML, Goyenechea A, Verdejo C et al (2007) Enterococcal endocarditis on native and prosthetic valves: a review of clinical and prognostic factors with emphasis on hospital-acquired infections as a major determinant of outcome. Medicine (Baltimore) 86(6):363–377Google Scholar
  67. 67.
    Fraher MH, Corcoran GD, Creagh S et al (2007) Daptomycin-resistant Enteroccoccus faecium in a patient with no prior exposure to daptomycin. J Hosp Infect 65(4):376–378PubMedGoogle Scholar
  68. 68.
    Gales AC, Jones RN, Andrade SS et al (2005) In vitro activity of tigecycline, a new glycylcycline, tested against 1,326 clinical bacterial strains isolated from Latin America. Braz J Infect Dis 9(5):348–356PubMedGoogle Scholar
  69. 69.
    Gales AC, Sader HS, Jones RN (2005) Antimicrobial activity of dalbavancin tested against Gram-positive clinical isolates from Latin American medical centres. Clin Microbiol Infect 11(2):95–100PubMedGoogle Scholar
  70. 70.
    Gavalda J, Len O, Miro JM, Munoz P et al (2007) Brief communication: treatment of Enterococcus faecalis endocarditis with ampicillin plus ceftriaxone. Ann Intern Med 146(8):574–579PubMedGoogle Scholar
  71. 71.
    Geraci JE, Martin WJ (1954) Antibiotic therapy of bacterial endocarditis. Circulation 10:173–194PubMedGoogle Scholar
  72. 72.
    Gerrits MM, Berning M, Van Vliet AH et al (2003) Effects of 16 S rRNA gene mutations on tetracycline resistance in Helicobacter pylori. Antimicrob Agents Chemother 47(9):2984–2986PubMedGoogle Scholar
  73. 73.
    Goll C, Balmer P, Schwab F, Ruden H et al (2007) Different trends of MRSA and VRE in a German hospital, 1999–2005. Infection 35(4):245–249PubMedGoogle Scholar
  74. 74.
    Gonzales RD, Schreckenberger PC, Graham MB et al (2001) Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid. Lancet 357(9263):1179PubMedGoogle Scholar
  75. 75.
    Gorbach SL (1993) Intraabdominal infections. Clin Infect Dis 17(6):961–965PubMedGoogle Scholar
  76. 76.
    Graham PL 3rd (2002) Staphylococcal and enterococcal infections in the neonatal intensive care unit. Semin Perinatol 26(5):322–331PubMedGoogle Scholar
  77. 77.
    Green MR, Anasetti C, Sandin RL et al (2006) Development of daptomycin resistance in a bone marrow transplant patient with vancomycin-resistant Enterococcus durans. J Oncol Pharm Pract 12(3):179–181PubMedGoogle Scholar
  78. 78.
    Grundmann H, Hellriegel B (2006) Mathematical modelling: a tool for hospital infection control. Lancet Infect Dis 6(1):39–45PubMedGoogle Scholar
  79. 79.
    Guskey MT, Tsuji BT (2010). A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin. Pharmacotherapy 30(1):80–94PubMedGoogle Scholar
  80. 80.
    Hanberger H, Nilsson LE, Maller R et al (1991) Pharmacodynamics of daptomycin and vancomycin on Enterococcus faecalis and Staphylococcus aureus demonstrated by studies of initial killing and postantibiotic effect and influence of Ca2+ and albumin on these drugs. Antimicrob Agents Chemother 35(9):1710–1716PubMedGoogle Scholar
  81. 81.
    Harbarth S, Uckay I (2004) Are there patients with peritonitis who require empiric therapy for enterococcus? Eur J Clin Microbiol Infect Dis 23(2):73–77PubMedGoogle Scholar
  82. 82.
    Havard CWH, Garrod LP, Waterworth PM (1959) Deaf or dead? a case of sub acute bacterial endocarditis treated with penicillin and streptomycin. Brit Med J 1:688–689PubMedGoogle Scholar
  83. 83.
    Hawkey PM (2008) Pre-clinical experience with daptomycin. J Antimicrob Chemother 62(Suppl 3):iii7–iii14Google Scholar
  84. 84.
    Hegde SS, Reyes N, Wiens T et al (2004) Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent, against gram-positive bacteria. Antimicrob Agents Chemother 48(8):3043–3050PubMedGoogle Scholar
  85. 85.
    Henning KJ, Delencastre H, Eagan J et al (1996) Vancomycin-resistant Enterococcus faecium on a pediatric oncology ward: duration of stool shedding and incidence of clinical infection. Pediatr Infect Dis J 15(10):848–854PubMedGoogle Scholar
  86. 86.
    Herrero IA, Issa NC, Patel R (2002) Nosocomial spread of linezolid-resistant, vancomycin-resistant Enterococcus faecium. N Engl J Med 346(11):867–869PubMedGoogle Scholar
  87. 87.
    Hidron AI, Edwards JR, Patel J et al (2008) NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006–2007. Infect Control Hosp Epidemiol 29(11):996–1011PubMedGoogle Scholar
  88. 88.
    Hidron AI, Schuetz AN, Nolte FS et al (2008) Daptomycin resistance in Enterococcus faecalis prosthetic valve endocarditis. J Antimicrob Chemother 61(6):1394–1396PubMedGoogle Scholar
  89. 89.
    Hinshaw RR, Schaadt RD, Murray B et al (2008) Spontaneous mutations frequency and serial passage resistance development studies with ceftaroline, 2008. In: 48th Annual interscience conference on antimicrobial agents and chemotherapy and the Infectious Diseases Society of America, 46th annual meeting, Washington, DC. Paper C1-185Google Scholar
  90. 90.
    Hunter TH (1947) Use of streptomycin in the treatment of bacterial endocarditis. Am J Med 2:436–442PubMedGoogle Scholar
  91. 91.
    Jacqueline C, Amador G, Batrd E et al (2008) Assessment of the in vitro activity of ceftaroline against vancomycin susceptible and resistant Enterococcus faecalis strains in a rabit endocarditis model: comparison with linezolid and vancomycin, 2008. In: 48th Annual interscience conference on antimicrobial agents and chemotherapy and the Infectious Diseases Society of America, 46th annual meeting, Washington, DC. Paper B-068Google Scholar
  92. 92.
    Jana S, Deb JK (2005) Molecular targets for design of novel inhibitors to circumvent aminoglycoside resistance. Curr Drug Targets 6(3):353–361PubMedGoogle Scholar
  93. 93.
    Jauregui LE, Babazadeh S, Seltzer E et al (2005) Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin Infect Dis 41(10):1407–1415PubMedGoogle Scholar
  94. 94.
    Jenkins I (2007) Linezolid- and vancomycin-resistant Enterococcus faecium endocarditis: successful treatment with tigecycline and daptomycin. J Hosp Med 2(5):343–344PubMedGoogle Scholar
  95. 95.
    Jones RN, Deshpande LM, Mutnick AH et al (2002) In vitro evaluation of BAL9141, a novel parenteral cephalosporin active against oxacillin-resistant staphylococci. J Antimicrob Chemother 50(6):915–932PubMedGoogle Scholar
  96. 96.
    Judice JK, Pace JL (2003) Semi-synthetic glycopeptide antibacterials. Bioorg Med Chem Lett 13(23):4165–4168PubMedGoogle Scholar
  97. 97.
    Kanafani ZA, Federspiel JJ, Fowler VG Jr (2007) Infective endocarditis caused by daptomycin-resistant Enterococcus faecalis: a case report. Scand J Infect Dis 39(1):75–77PubMedGoogle Scholar
  98. 98.
    Karanfil LV, Murphy M, Josephson A et al (1992) A cluster of vancomycin-resistant Enterococcus faecium in an intensive care unit. Infect Control Hosp Epidemiol 13(4):195–200PubMedGoogle Scholar
  99. 99.
    Kariyama R, Kumon H, Chow L et al (1998) In-vitro activity of the combination of ampicillin and arbekacin against high-level gentamicin-resistant enterococci. J Antimicrob Chemother 42(6):836–838PubMedGoogle Scholar
  100. 100.
    Kim KS, Bayer AS (1987) Significance of in-vitro penicillin tolerance in experimental enterococcal endocarditis. J Antimicrob Chemother 19(4):475–485PubMedGoogle Scholar
  101. 101.
    Ko KS, Baek JY, Lee JY et al (2005) Molecular characterization of vancomycin-resistant Enterococcus faecium isolates from Korea. J Clin Microbiol 43(5):2303–2306PubMedGoogle Scholar
  102. 102.
    Kobayashi N, Alam M, Nishimoto Y et al (2001) Distribution of aminoglycoside resistance genes in recent clinical isolates of Enterococcus faecalis, Enterococcus faecium and Enterococcus avium. Epidemiol Infect 126(2):197–204PubMedGoogle Scholar
  103. 103.
    Koh TH, Hsu LY, Chiu LL et al (2006) Emergence of epidemic clones of vancomycin-resistant Enterococcus faecium in Singapore. J Hosp Infect 63(2):234–236PubMedGoogle Scholar
  104. 104.
    Kotra LP, Haddad J, Mobashery S (2000) Aminoglycosides: perspectives on mechanisms of action and resistance and strategies to counter resistance. Antimicrob Agents Chemother 44(12):3249–3256PubMedGoogle Scholar
  105. 105.
    Krcmery V, Bilikova E, Svetlansky I et al (2001) Is vancomycin resistance in enterococci predictive of inferior outcome of enterococcal bacteremia? Clin Infect Dis 32(7):1110–1112PubMedGoogle Scholar
  106. 106.
    Lautenbach E, Schuster MG, Bilker WB et al (1998) The role of chloramphenicol in the treatment of bloodstream infection due to vancomycin-resistant Enterococcus. Clin Infect Dis 27(5):1259–1265PubMedGoogle Scholar
  107. 107.
    Leavis HL, Willems RJ, Top J et al (2003) Epidemic and nonepidemic multidrug-resistant Enterococcus faecium. Emerg Infect Dis 9(9):1108–1115PubMedGoogle Scholar
  108. 108.
    Leavis HL, Bonten MJ, Willems RJ (2006) Identification of high-risk enterococcal clonal complexes: global dispersion and antibiotic resistance. Curr Opin Microbiol 9(5):454–460PubMedGoogle Scholar
  109. 109.
    Leclercq R, Derlot E, Duval J et al (1988). Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium. N Engl J Med. 1988 (3):157–161Google Scholar
  110. 110.
    Lefort A, Saleh-Mghir A, Garry L et al (2000) Activity of LY333328 combined with gentamicin in vitro and in rabbit experimental endocarditis due to vancomycin-susceptible or –resistant Enterococcus faecalis. Antimicrob Agents Chemother 44(11):3017–3021PubMedGoogle Scholar
  111. 111.
    Lefort A, Lafaurie M, Massias L et al (2003) Activity and diffusion of tigecycline (GAR-936) in experimental enterococcal endocarditis. Antimicrob Agents Chemother 47(1):216–222PubMedGoogle Scholar
  112. 112.
    Lentino JR, Narita M, Yu VL (2008) New antimicrobial agents as therapy for resistant gram-positive cocci. Eur J Clin Microbiol Infect Dis 27(1):3–15PubMedGoogle Scholar
  113. 113.
    Leonard SN, Rybak MJ (2008) Telavancin: an antimicrobial with a multifunctional mechanism of action for the treatment of serious gram-positive infections. Pharmacotherapy 28(4):458–468PubMedGoogle Scholar
  114. 114.
    Lesho EP, Wortmann GW, Craft D et al (2006) De novo daptomycin nonsusceptibility in a clinical isolate. J Clin Microbiol 44(2):673PubMedGoogle Scholar
  115. 115.
    Lester CH, Sandvang D, Olsen SS et al (2008) Emergence of ampicillin-resistant Enterococcus faecium in Danish hospitals. J Antimicrob Chemother 62(6):1203–1206PubMedGoogle Scholar
  116. 116.
    Lewis JS 2nd, Owens A, Cadena J, Sabol K et al (2005) Emergence of daptomycin resistance in Enterococcus faecium during daptomycin therapy. Antimicrob Agents Chemother 49(4):1664–1665PubMedGoogle Scholar
  117. 117.
    Linden PK, Pasculle AW, Manez R et al (1996) Differences in outcomes for patients with bacteremia due to vancomycin-resistant Enterococcus faecium or vancomycin-susceptible E. faecium. Clin Infect Dis 22(4):663–670Google Scholar
  118. 118.
    Linden PK, Moellering RC Jr, Wood CA et al (2001) Treatment of vancomycin-resistant Enterococcus faecium infections with quinupristin/dalfopristin. Clin Infect Dis 33(11):1816–1823PubMedGoogle Scholar
  119. 119.
    Livermore DM (2005) Tigecycline: what is it, and where should it be used? J Antimicrob Chemother 56(4):611–614PubMedGoogle Scholar
  120. 120.
    Long JK, Choueiri TK, Hall GS et al (2005) Daptomycin-resistant Enterococcus faecium in a patient with acute myeloid leukemia. Mayo Clin Proc 80(9):1215–1216PubMedGoogle Scholar
  121. 121.
    Lopardo H, Casimir L, Hernández C, Rubeglio EA (1990). Isolation of three strains of beta-lactamase-producing Enterococcus faecalis in Argentina. Eur J Clin Microbiol Infect Dis 9(6):402–405PubMedGoogle Scholar
  122. 122.
    Lucet JC, Armand-Lefevre L, Laurichesse JJ et al (2007) Rapid control of an outbreak of vancomycin-resistant enterococci in a French university hospital. J Hosp Infect 67(1):42–48PubMedGoogle Scholar
  123. 123.
    Mainardi JL, Gutmann L, Acar JF et al (1995) Synergistic effect of amoxicillin and cefotaxime against Enterococcus faecalis. Antimicrob Agents Chemother 39(9):1984–1987PubMedGoogle Scholar
  124. 124.
    Mainardi JL, Legrand R, Arthur M et al (2000) Novel mechanism of beta-lactam resistance due to bypass of DD-transpeptidation in Enterococcus faecium. J Biol Chem 275(22):16490–16496PubMedGoogle Scholar
  125. 125.
    Mandel GL, Kaye D, Levinson ME et al (1970) Enteroccal endocarditis. Arch Int Med 125:258–264Google Scholar
  126. 126.
    Maschmeyer G, Haas A (2008) The epidemiology and treatment of infections in cancer patients. Int J Antimicrob Agents 31(3):193–197PubMedGoogle Scholar
  127. 127.
    Matsumura S, Simor AE (1998) Treatment of endocarditis due to vancomycin-resistant Enterococcus faecium with quinupristin/dalfopristin, doxycycline, and rifampin: a synergistic drug combination. Clin Infect Dis 27(6):1554–1556PubMedGoogle Scholar
  128. 128.
    McBride SM, Fischetti VA, Leblanc DJ et al (2007) Genetic diversity among Enterococcus faecalis. PLoS One 2(7):e582PubMedGoogle Scholar
  129. 129.
    McNeeley DF, Saint-Louis F, Noel GJ (1996) Neonatal enterococcal bacteremia: an increasingly frequent event with potentially untreatable pathogens. Pediatr Infect Dis J 15(9):800–805PubMedGoogle Scholar
  130. 130.
    Megran DW (1992) Enterococcal endocarditis. Clin Infect Dis 15(1):63–71PubMedGoogle Scholar
  131. 131.
    Moellering RC Jr (1991) The Garrod lecture. The enterococcus: a classic example of the impact of antimicrobial resistance on therapeutic options. J Antimicrob Chemother 28(1):1–12Google Scholar
  132. 132.
    Moellering RC Jr (1999) A novel antimicrobial agent joins the battle against resistant bacteria. Ann Intern Med 130(2):155–157PubMedGoogle Scholar
  133. 133.
    Moellering RC (2003) Linezolid: the first oxazolidinone antimicrobial. Ann Intern Med 138(2):135–142PubMedGoogle Scholar
  134. 134.
    Moellering RC Jr, Wennersten C, Weinberg AN (1971) Studies on antibiotic synergism against enterococci. I. Bacteriologic studies. J Lab Clin Med 77(5):821–828Google Scholar
  135. 135.
    Munoz-Price LS, Lolans K, Quinn JP (2005) Emergence of resistance to daptomycin during treatment of vancomycin-resistant Enterococcus faecalis infection. Clin Infect Dis 41(4):565–566PubMedGoogle Scholar
  136. 136.
    Murphy TM, Deitz JM, Petersen PJ et al (2000) Therapeutic efficacy of GAR-936, a novel glycylcycline, in a rat model of experimental endocarditis. Antimicrob Agents Chemother 44(11):3022–3027PubMedGoogle Scholar
  137. 137.
    Murray BE, Mederski-Samaroj B (1983). Transferable beta-lactamase. A new mechanism for in vitro penicillin resistance in Streptococcus faecalis. J Clin Invest 72(3):1168–1171.Google Scholar
  138. 138.
    Murray BE (1990) The life and times of the Enterococcus. Clin Microbiol Rev 3(1):46–65PubMedGoogle Scholar
  139. 139.
    Murray BE, Lopardo HA, Rubeglio EA et al (1992). Intrahospital spread of a single gentamicin-resistant, beta-lactamase-producing strain of Enterococcus faecalis in Argentina. Antimicrob Agents Chemother 36(1):230–232PubMedGoogle Scholar
  140. 140.
    Murray BE (2000) Vancomycin-resistant enterococcal infections. N Engl J Med 342(10):710–721PubMedGoogle Scholar
  141. 141.
    Mutnick AH, Biedenbach DJ, Jones RN (2003) Geographic variations and trends in antimicrobial resistance among Enterococcus faecalis and Enterococcus faecium in the SENTRY Antimicrobial Surveillance Program (1997–2000). Diagn Microbiol Infect Dis 46(1):63–68PubMedGoogle Scholar
  142. 142.
    Nallapareddy SR, Wenxiang H, Weinstock GM et al (2005) Molecular characterization of a widespread, pathogenic, and antibiotic resistance-receptive Enterococcus faecalis lineage and dissemination of its putative pathogenicity island. J Bacteriol 187(16):5709–5718PubMedGoogle Scholar
  143. 143.
    Nallapareddy SR, Singh KV, Okhuysen PC et al (2008) A functional collagen adhesin gene, acm, in clinical isolates of Enterococcus faecium correlates with the recent success of this emerging nosocomial pathogen. Infect Immun 76(9):4110–4119PubMedGoogle Scholar
  144. 144.
    National Nosocomial Infections Surveillance (NNIS) (2004) System report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 32(8):470–485Google Scholar
  145. 145.
    Nicas TI, Mullen DL, Flokowitsch JE, Preston DA et al (1996) Semisynthetic glycopeptides antibiotics derived from LY264826 active against vancomycin-resistant enterococci. Antimicrob Agents Chemother 40(9):2194–2199PubMedGoogle Scholar
  146. 146.
    Norris AH, Reilly JP, Edelstein PH et al (1995) Chloramphenicol for the treatment of vancomycin-resistant enterococcal infections. Clin Infect Dis 20(5):1137–1144PubMedGoogle Scholar
  147. 147.
    Noskin GA (2005) Tigecycline: a new glycylcycline for treatment of serious infections. Clin Infect Dis 41(Suppl 5):S303–S314PubMedGoogle Scholar
  148. 148.
    Ofner-Agostini M, Johnston BL, Simor AE et al (2008). Vancomycin-resistant enterococci in Canada: results from the Canadian nosocomial infection surveillance program, 1999–2005. Infect Control Hosp Epidemiol 29(3):271–274PubMedGoogle Scholar
  149. 149.
    Olaison L, Schadewitz K (2002) Enterococcal endocarditis in Sweden, 1995–1999: can shorter therapy with aminoglycosides be used? Clin Infect Dis 34(2):159–166PubMedGoogle Scholar
  150. 150.
    Olofsson MB, Pornull KJ, Karnell A et al (2001) Fecal carriage of vancomycin- and ampicillin-resistant enterococci observed in Swedish adult patients with diarrhea but not among healthy subjects. Scand J Infect Dis 33(9):659–662PubMedGoogle Scholar
  151. 151.
    Ono S, Muratani T, Matsumoto T (2005) Mechanisms of resistance to imipenem and ampicillin in Enterococcus faecalis. Antimicrob Agents Chemother 49(7):2954–2958PubMedGoogle Scholar
  152. 152.
    Panesso D, Ospina S, Robledo J et al (2002) First characterization of a cluster of VanA-type glycopeptide-resistant Enterococcus faecium, Colombia. Emerg Infect Dis 8(9):961–965PubMedGoogle Scholar
  153. 153.
    Panesso D, Reyes J, Zurita J et al (2008) Molecular characterization of vancomycin resistant enterococci from Latin-American hospitals: a prospective study, 2006–2007. In: 48th Annual interscience conference on antimicrobial agents and chemotherapy and the Infectious Diseases Society of America, 46th annual Meeting, Washington, DC. Paper C2-1998Google Scholar
  154. 154.
    Patel R (2003) Clinical impact of vancomycin-resistant enterococci. J Antimicrob Chemother (Suppl 3):iii13–iii21Google Scholar
  155. 155.
    Patel R, Allen SL, Manahan JM et al (2001) Natural history of vancomycin-resistant enterococcal colonization in liver and kidney transplant recipients. Liver Transpl 7(1):27–31PubMedGoogle Scholar
  156. 156.
    Patterson JE, Singh KV, Murray BE (1991). Epidemiology of an endemic strain of beta-lactamase-producing Enterococcus faecalis. J Clin Microbiol 29(11):2513–2516PubMedGoogle Scholar
  157. 157.
    Paterson DL, Muto CA, Ndirangu M et al (2008). Acquisition of rectal colonization by vancomycin-resistant Enterococcus among intensive care unit patients treated with piperacillin-tazobactam versus those receiving cefepime-containing antibiotic regimens. Antimicrob Agents Chemother 52(2):465–469PubMedGoogle Scholar
  158. 158.
    Peleg AY, Potoski BA, Rea R et al (2007) Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary report. J Antimicrob Chemother 59(1):128–131PubMedGoogle Scholar
  159. 159.
    Perez Salmeron J, Martinez Garcia F, Roldan Conesa D et al (2006) Comparative study of treatment with quinupristin-dalfopristin alone or in combination with gentamicin, teicoplanin, imipenem or levofloxacin in experimental endocarditis due to a multidrug-resistant Enterococcus faecium. Rev Esp Quimioter 19(3):258–266PubMedGoogle Scholar
  160. 160.
    Perri MB, Hershberger E, Ionescu M et al (2002) In vitro susceptibility of vancomycin-resistant enterococci (VRE) to fosfomycin. Diagn Microbiol Infect Dis 42(4):269–271PubMedGoogle Scholar
  161. 161.
    Pogue JM, Paterson DL, Pasculle AW et al (2007) Determination of risk factors associated with isolation of linezolid-resistant strains of vancomycin-resistant Enterococcus. Infect Control Hosp Epidemiol 28(12):1382–1388PubMedGoogle Scholar
  162. 162.
    Pootoolal J, Neu J, Wright GD (2002) Glycopeptide antibiotic resistance. Annu Rev Pharmacol Toxicol 42:381–408PubMedGoogle Scholar
  163. 163.
    Poyart C, Lambert T, Morand P et al (2002) Native valve endocarditis due to Enterococcus hirae. J Clin Microbiol 40(7):2689–2690PubMedGoogle Scholar
  164. 164.
    Reid KC, Cockerill IF, Patel R (2001) Clinical and epidemiological features of Enterococcus casseliflavus/flavescens and Enterococcus gallinarum bacteremia: a report of 20 cases. Clin Infect Dis 32(11):1540–1546PubMedGoogle Scholar
  165. 165.
    Reid GE, Grim SA, Aldeza CA et al (2007) Rapid development of Acinetobacter baumannii resistance to tigecycline. Pharmacotherapy 27(8):1198–1201PubMedGoogle Scholar
  166. 166.
    Rello J (2005) Pharmacokinetics, pharmacodynamics, safety and tolerability of tigecycline. J Chemother 17(Suppl 1):12–22PubMedGoogle Scholar
  167. 167.
    Ricaurte JC, Boucher HW, Turett GS et al (2001) Chloramphenicol treatment for vancomycin-resistant Enterococcus faecium bacteremia. Clin Microbiol Infect 7(1):17–21PubMedGoogle Scholar
  168. 168.
    Rice LB, Eliopoulos GM, Wennersten C et al (1991). Chromosomally mediated beta-lactamase production and gentamicin resistance in Enterococcus faecalis. Antimicrob Agents Chemother 35(2):272–276PubMedGoogle Scholar
  169. 169.
    Rice LB, Carias L, Rudin S et al (2003) A potential virulence gene, hylEfm, predominates in Enterococcus faecium of clinical origin. J Infect Dis 187(3):508–512PubMedGoogle Scholar
  170. 170.
    Rice LB, Lakticova V, Carias LL et al (2009) Transferable capacity for gastrointestinal colonization in Enterococcus faecium in a mouse model. J Infect Dis 199(3):342–349PubMedGoogle Scholar
  171. 171.
    Rodloff AC, Leclercq R, Debbia EA et al (2008) Comparative analysis of antimicrobial susceptibility among organisms from France, Germany, Italy, Spain and the UK as part of the tigecycline evaluation and surveillance trial. Clin Microbiol Infect 14(4):307–314PubMedGoogle Scholar
  172. 172.
    Roghmann MC, McCarter RJ Jr, Brewrink J et al (1997) Clostridium difficile infection is a risk factor for bacteremia due to vancomycin-resistant enterococci (VRE) in VRE-colonized patients with acute leukemia. Clin Infect Dis 25(5):1056–1059PubMedGoogle Scholar
  173. 173.
    Roghmann MC, Qaiyumi S, Schwalbe R et al (1997) Natural history of colonization with vancomycin-resistant Enterococcus faecium. Infect Control Hosp Epidemiol 18(10):679–680PubMedGoogle Scholar
  174. 174.
    Ross JI, Eady EA, Cove JH et al (1998) 16 S rRNA mutation associated with tetracycline resistance in a gram-positive bacterium. Antimicrob Agents Chemother 42(7):1702–1705PubMedGoogle Scholar
  175. 175.
    Sader HS, Jones RN, Andrade-Baiocchi S, et al (2002). Four-year evaluation of frequency of occurrence and antimicrobial susceptibility patterns of bacteria from bloodstream infections in Latin American medical centers. Diagn Microbiol Infect Dis 44(3):273–280PubMedGoogle Scholar
  176. 176.
    Sahm DF, Kissinger J, Gilmore MS et al (1989) In vitro susceptibility studies of vancomycin-resistant Enterococcus faecalis. Antimicrob Agents Chemother 33(9):1588–1591PubMedGoogle Scholar
  177. 177.
    Sakka V, Tsiodras S, Galani L et al (2008) Risk-factors and predictors of mortality in patients colonised with vancomycin-resistant enterococci. Clin Microbiol Infect 14(1):14–21PubMedGoogle Scholar
  178. 178.
    Saleh-Mghir A, Lefort A, Petegnief Y et al (1999) Activity and diffusion of LY333328 in experimental endocarditis due to vancomycin-resistant Enterococcus faecalis. Antimicrob Agents Chemother 43(1):115–120PubMedGoogle Scholar
  179. 179.
    Salgado CD, Farr BM (2003) Outcomes associated with vancomycin-resistant enterococci: a meta-analysis. Infect Control Hosp Epidemiol 24(9):690–698PubMedGoogle Scholar
  180. 180.
    Sauermann R, Rothenburger M, Graninger W et al (2008) Daptomycin: a review 4 years after first approval. Pharmacology 81(2):79–91PubMedGoogle Scholar
  181. 181.
    Schutt AC, Bohm NM (2009) Multidrug-resistant enterococcus faecium endocarditis treated with combination tigecycline and high-dose daptomycin. Ann Pharmacother 43(12):2108–2112PubMedGoogle Scholar
  182. 182.
    Shankar N, Lockatell CV, Baghdayan AS et al (2001) Role of Enterococcus faecalis surface protein Esp in the pathogenesis of ascending urinary tract infection. Infect Immun 69(7):4366–4372PubMedGoogle Scholar
  183. 183.
    Shaw JP, Seroogy J, Kaniga K et al (2005) Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects. Antimicrob Agents Chemother 49(1):195–201PubMedGoogle Scholar
  184. 184.
    Silverman JA, Perlmutter NG, Shapiro HM (2003) Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus. Antimicrob Agents Chemother 47(8):2538–2544PubMedGoogle Scholar
  185. 185.
    Singh KV, Murray BE (2005) Differences in the Enterococcus faecalis lsa locus that influence susceptibility to quinupristin-dalfopristin and clindamycin. Antimicrob Agents Chemother 49(1):32–39PubMedGoogle Scholar
  186. 186.
    Singh KV, Weinstock GM, Murray BE (2002) An Enterococcus faecalis ABC homologue (Lsa) is required for the resistance of this species to clindamycin and quinupristin-dalfopristin. Antimicrob Agents Chemother 46(6):1845–1850PubMedGoogle Scholar
  187. 187.
    Slee AM, Wuonola MA, McRipley RJ et al (1987) Oxazolidinones, a new class of synthetic antibacterial agents: in vitro and in vivo activities of DuP 105 and DuP 721. Antimicrob Agents Chemother 31(11):1791–1797PubMedGoogle Scholar
  188. 188.
    Slover CM, Rodvold KA, Danziger LH (2007) Tigecycline: a novel broad-spectrum antimicrobial. Ann Pharmacother 41(6):965–972PubMedGoogle Scholar
  189. 189.
    Smith CA, Baker EN (2002) Aminoglycoside antibiotic resistance by enzymatic deactivation. Curr Drug Targets Infect Disord 2(2):143–160PubMedGoogle Scholar
  190. 190.
    Solomkin JS, Mazuski JE, Baron EJ et al (2003) Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections. Clin Infect Dis 37(8):997–1005PubMedGoogle Scholar
  191. 191.
    Speer BS, Salyers AA (1989) Novel aerobic tetracycline resistance gene that chemically modifies tetracycline. J Bacteriol 171(1):148–153PubMedGoogle Scholar
  192. 192.
    Stevens MP, Edmond MB (2005) Endocarditis due to vancomycin-resistant enterococci: case report and review of the literature. Clin Infect Dis 41(8):1134–1142PubMedGoogle Scholar
  193. 193.
    Stosor V, Peterson LR, Postelnick M et al (1998) Enterococcus faecium bacteremia: does vancomycin resistance make a difference? Arch Intern Med 158(5):522–527PubMedGoogle Scholar
  194. 194.
    Streit JM, Sader HS, Fritsche TR et al (2005) Dalbavancin activity against selected populations of antimicrobial-resistant Gram-positive pathogens. Diagn Microbiol Infect Dis 53(4):307–310PubMedGoogle Scholar
  195. 195.
    Stryjewski ME, Graham DR, Wilson SE et al (2008) Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms. Clin Infect Dis 46(11):1683–1693PubMedGoogle Scholar
  196. 196.
    Sullivan A, Edlund C, Nord CE (2001) Effect of antimicrobial agents on the ecological balance of human microflora. Lancet Infect Dis 1(2):101–114PubMedGoogle Scholar
  197. 197.
    Tacconelli E, Cataldo MA (2008) Vancomycin-resistant enterococci (VRE): transmission and control. Int J Antimicrob Agents 31(2):99–106PubMedGoogle Scholar
  198. 198.
    Timmers GJ, van der Zwet WC, Simoons-Smit IM et al (2002) Outbreak of vancomycin-resistant Enterococcus faecium in a haematology unit: risk factor assessment and successful control of the epidemic. Br J Haematol 116(4):826–833PubMedGoogle Scholar
  199. 199.
    Toh SM, Xiong L, Arias CA et al (2007) Acquisition of a natural resistance gene renders a clinical strain of methicillin-resistant Staphylococcus aureus resistant to the synthetic antibiotic linezolid. Mol Microbiol 64(6):1506–1514PubMedGoogle Scholar
  200. 200.
    Toledo-Arana A, Valle J, Solano C et al (2001) The enterococcal surface protein, Esp, is involved in Enterococcus faecalis biofilm formation. Appl Environ Microbiol 67(10):4538–4545PubMedGoogle Scholar
  201. 201.
    Top J, Willems R, van der Velden S, Asbroek M et al (2008) Emergence of clonal complex 17 Enterococcus faecium in the Netherlands. J Clin Microbiol 46(1):214–219PubMedGoogle Scholar
  202. 202.
    Torell E, Fredlund H, Tornquist E et al (1997) Intrahospital spread of vancomycin-resistant Enterococcus faecium in Sweden. Scand J Infect Dis 29(3):259–263PubMedGoogle Scholar
  203. 203.
    Trieber CA, Taylor DE (2002) Mutations in the 16 S rRNA genes of Helicobacter pylori mediate resistance to tetracycline. J Bacteriol 184(8):2131–2140PubMedGoogle Scholar
  204. 204.
    Tsigrelis C, Singh KV, Coutinho TD et al (2007) Vancomycin-resistant Enterococcus faecalis endocarditis: linezolid failure and strain characterization of virulence factors. J Clin Microbiol 45(2):631–635PubMedGoogle Scholar
  205. 205.
    Uttley AH, Collins CH, Naidoo J et al (1988). Vancomycin-resistant enterococci. Lancet 1(8575–6):57–58PubMedGoogle Scholar
  206. 206.
    Valdezate S, Labayru C, Navarro A et al (2009) Large clonal outbreak of multidrug-resistant CC17 ST17 Enterococcus faecium containing Tn5382 in a Spanish hospital. J Antimicrob Chemother 63(1):17–20PubMedGoogle Scholar
  207. 207.
    Van den Bogaard AE, Bruinsma N, Stobberingh EE (2000) The effect of banning avoparcin on VRE carriage in The Netherlands. J Antimicrob Chemother 46(1):146–148PubMedGoogle Scholar
  208. 208.
    Van den Braak N, Van Belkum A, Van Keulen M et al (1998) Molecular characterization of vancomycin-resistant enterococci from hospitalized patients and poultry products in The Netherlands. J Clin Microbiol 36(7):1927–1932PubMedGoogle Scholar
  209. 209.
    Weisblum B (1995) Insights into erythromycin action from studies of its activity as inducer of resistance. Antimicrob Agents Chemother 39(4):797–805PubMedGoogle Scholar
  210. 210.
    Wells VD, Wong ES, Murray BE et al (1992). Infections due to beta-lactamase-producing, high-level gentamicin-resistant Enterococcus faecalis. Ann Intern Med 116(4):285–292PubMedGoogle Scholar
  211. 211.
    Werner G, Klare I, Fleige C et al (2008) Increasing rates of vancomycin resistance among Enterococcus faecium isolated from German hospitals between 2004 and 2006 are due to wide clonal dissemination of vancomycin-resistant enterococci and horizontal spread of vanA clusters. Int J Med Microbiol 298(5–6):515–527Google Scholar
  212. 212.
    Whitman MS, Pitsakis PG, Zausner A et al (1993) Antibiotic treatment of experimental endocarditis due to vancomycin- and ampicillin-resistant Enterococcus faecium. Antimicrob Agents Chemother 37(10):2069–2073PubMedGoogle Scholar
  213. 213.
    Willems RJ, Bonten MJ (2007) Glycopeptide-resistant enterococci: deciphering virulence, resistance and epidemicity. Curr Opin Infect Dis 20(4):384–390PubMedGoogle Scholar
  214. 214.
    Willems RJ, Top J, van Santen M et al (2005) Global spread of vancomycin-resistant Enterococcus faecium from distinct nosocomial genetic complex. Emerg Infect Dis 11(6):821–828PubMedGoogle Scholar
  215. 215.
    Wisplinghoff H, Bischoff T, Tallent SM et al (2004) Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 39(3):309–317PubMedGoogle Scholar
  216. 216.
    Wright GD (1999) Aminoglycoside-modifying enzymes. Curr Opin Microbiol 2(5):499–503PubMedGoogle Scholar
  217. 217.
    Zarrilli R, Tripodi MF, Di Popolo A et al (2005) Molecular epidemiology of high-level aminoglycoside-resistant enterococci isolated from patients in a university hospital in southern Italy. J Antimicrob Chemother 56(5):827–835PubMedGoogle Scholar
  218. 218.
    Zhanel GG, Hoban DJ, Karlowsky JA (2001) Nitrofurantoin is active against vancomycinresistant enterococci. Antimicrob Agents Chemother 45(1):324–326PubMedGoogle Scholar
  219. 219.
    Zhou Q, Moore C, Eden S et al (2008) Factors associated with acquisition of vancomycin-resistant enterococci (VRE) in roommate contacts of patients colonized or infected with VRE in a tertiary care hospital. Infect Control Hosp Epidemiol 29(5):398–403PubMedGoogle Scholar
  220. 220.
    Zimmer SM, Caliendo AM, Thigpen MC et al (2003) Failure of linezolid treatment for enterococcal endocarditis. Clin Infect Dis 37(3):e29–e30PubMedGoogle Scholar
  221. 221.
    Zimmermann RA, Moellering RC Jr, Weinberg AN (1971) Mechanism of resistance to antibiotic synergism in enterococci. J Bacteriol 105(3):873–879PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Division of Pediatrics Infectious DiseasesUniversity of Texas Medical School at HoustonHoustonUSA
  2. 2.Division of Infectious DiseasesUniversity of Texas Medical School at HoustonHoustonUSA
  3. 3.Molecular Genetics and Antimicrobial Resistance UnitUniversidad El BosqueBogotáColombia

Personalised recommendations